NIKKEI 225
39,492.03 +318.88 (+0.81%) HANG SENG
17,934.63 -138.27 (-0.77%) CRUDE OIL
80.94 +0.11 (+0.14%) GOLD FUTURES
2,331.80 +1.00 (+0.04%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,855.39 +1,317.58 (+2.77%)
EDIT Jan 2025 15.000 put
| Previous close | 9.36 |
| Open | 8.50 |
| Bid | 9.60 |
| Ask | 12.00 |
| Strike | 15.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.50 - 9.36 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
ZacksEditas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
GlobeNewswireEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
- GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster presentation on Friday, June 14 at 6 p.m. CEST/Noon EDT CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
